This is a regenerative biomedical technology, which aims to address the human chronic lung diseases that currently has no pharmaceutical approach for efficient controltherapy, such as COPDlung fibrosis. The principle is to induce the in vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factor BMI1, which potentiates the repair of injured tissues.

Instead of transplanting in vitro propagated stem cells to injured organ, the current technology induces vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factors. This technology avoids the complexity of in vitro propagation of stem cellssafety concerns,induces more efficient tissue regeneration because of the intrinsic property of target cells.

COPDlung fibrosis are major public health problems with highgrowing prevalences globally. Unfortunately, no pharmaceutical approach to date was able to controlrestore the syndrome of these diseases. The current technology induces lung tissue repair based on in vivo reprogramming of endogenous lung epithelial cells, holding promise to be first therapeutic approach for these diseases.